SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is experiencing a dramatic surge driven by rising oil prices amidst escalating Middle East tensions and concerns over the Strait of Hormuz. The community is buzzing with talks of a significant short squeeze, high trading volumes, and the stock's potential for further explosive gains, leaving many shorts 'cooked'.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending as investors and the community are actively discussing its recent achievement of profitability, a $1B annualized direct revenue run rate, and over 25 million Snapchat+ subscribers, signaling a potential turnaround. Many believe the stock is significantly undervalued given these operational milestones and its leadership in AI/AR technology, fueling speculation of a potential acquisition.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending after reporting record Q4 and full-year 2025 revenue with significant profitability improvements, sparking community debate over its perceived undervaluation and multi-billion-dollar AI infrastructure pipeline against persistent skepticism regarding management's past execution and the stock's price action.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Escalating geopolitical tensions in the Middle East, driven by reported attacks on US interests and threats to the Strait of Hormuz, are sparking community debate on whether the market's current resilience is a manipulated 'patriotic bump' or a genuine buying opportunity amidst surging oil prices and anticipated volatility for the broader SPY.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is surging amid community excitement over a multi-billion dollar strategic investment by a leading AI chipmaker to advance optical infrastructure, reinforcing its perceived critical role in next-gen data centers, though its high valuation is actively debated among investors.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending downward following an earnings report revealing significantly higher capital expenditure plans and softer guidance, raising investor concerns about its debt and path to profitability. Despite the sharp decline, a divided community debates the long-term potential, with bulls emphasizing the company's substantial AI infrastructure backlog and recent bullish developments surrounding its key customer, OpenAI.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is trending as its major holdings, Samsung and SK Hynix, surge amidst the AI-driven memory supercycle and recent DRAM/NAND price hikes. While some debate if its parabolic gains represent a market bubble, others view current dips as tactical buying opportunities, citing robust fundamentals and attractive valuations compared to US benchmarks.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending amid escalating Middle East tensions and threats to oil shipping in the Strait of Hormuz, which are driving crude prices higher across the sector. The community is actively discussing INDO's potential to catch up to other booming energy stocks, alongside anticipation of news regarding its drilling operations.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is experiencing significant discussion after receiving FDA Breakthrough Therapy Designation for its Friedreich's Ataxia treatment, nomlabofusp, sparking bullish sentiment and comparisons to multi-billion dollar acquisitions, while a recently priced public offering at $5.00 per share drives ongoing debate regarding immediate dilution versus funding a promising pipeline.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending following stronger-than-expected Q4 earnings and a significant arbitration win against Shell. The community is actively discussing its advantageous position to capitalize on spiking global LNG prices, driven by escalating Middle East tensions and a halt in Qatar's production, alongside its rapid growth trajectory and perceived undervalued status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00

Citizens Jmp reduced their price objective on Crinetics Pharmaceuticals from $105.00 to $96.00 and set a "market outperform" rating for the company in a research note on Monday...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen

Wall Street Zen upgraded Crinetics Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

Crinetics Pharmaceuticals is Now Oversold (CRNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Vanguard Group Inc. Sells 86,003 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Vanguard Group Inc. trimmed its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 0.9% in the 3rd quarter, according to its most recent filing with the SEC. The institutional...

Crinetics Pharmaceuticals Q4 Earnings Call Highlights

Crinetics Pharmaceuticals (NASDAQ:CRNX) executives highlighted early commercial momentum for PALSONIFY, outlined a global phase II/III study plan for atumelnant in ACTH-dependent Cushing's syndrome...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts...

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +6.01% and +38.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

JPMorgan Chase & Co. Grows Stake in Crinetics Pharmaceuticals, Inc. $CRNX

JPMorgan Chase & Co. increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 279.2% during the 3rd quarter, according to the company in its most recent disclosure...

Preview: Crinetics Pharmaceuticals's Earnings

NEOS Investment Management LLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX

NEOS Investment Management LLC cut its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 61.6% in the 3rd quarter, according to the company in its most recent disclosure with...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$40.68
Prev Close	$41.10
Open	$40.46
Dividend Yield	0.00%
50-Day Moving Average	$48.59
Beta	1.16
Avg. Volume	1M
PE Ratio	-8.23

52-Week High	$57.99
52-Week Low	$24.10
Market Capitalization	$4.3B
EPS (Annual)	-$4.95
Price to Book	3.92
Revenue Per Employee	$12,956.23

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc